TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05441878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% albumin
Description: Albumin arm for resuscitation fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Description: Only Balanced salt solution will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced salt solution
Description: Only Balanced salt solution will be used.
Study: NCT00560521

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
Study: NCT03105544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation-based training
Description: As described under group descriptions
Study: NCT03175055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix
Description: The study to assess safety and efficacy of Phoenix medical exoskeleton.
Study: NCT02840084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen(TM) Ultrasound System
Description: Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts.
Study: NCT01331213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: FDA approved medication (capsules) at 200mg dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT00422513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 120-360 micrograms intravenous (iv) monthly, starting dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: As prescribed, iv, 3 times weekly
Study: NCT03897439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
Study: NCT06531967

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00289913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Infanrix™
Description: Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: PedvaxHIB™
Description: PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: PedvaxHIB™
Description: PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: PedvaxHIB™
Description: PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: PedvaxHIB™
Description: PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit.
Study: NCT06531967

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03262311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia marker
Description: Single oral dose of pimonidazole 500 mg/m2
Study: NCT00565929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile saline (0.9%).
Study: NCT00997516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILS appendectomy
Description: Use of SILSPort to perform laparoscopic appendectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic appendectomy
Description: conventional laparoscopic removal of the appendix
Study: NCT00565929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile saline (0.9%).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN
Description: The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10\^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10\^7 or 1X10\^8 TCID 50.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN
Description: The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10\^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10\^7 or 1X10\^8 TCID 50.
Study: NCT00443196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MiCK Assay
Description: Physician determined treatment
Study: NCT03999775

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium, vitamin D and bioactive collagen peptides supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and vitamin D supplement
Study: NCT02198001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
Description: BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
Description: BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os\> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: atraumatic extraction
Description: Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: atraumatic extraction
Description: Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
Study: NCT04248621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: LHRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: LHRH agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: LHRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: LHRH agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: LHRH agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: LHRH agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: LHRH antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: LHRH antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Antiandrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Antiandrogen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Antiandrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Antiandrogen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maximum androgen blockade
Description: Combination therapy with LHRH agonist and antiandrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum androgen blockade
Description: Combination therapy with LHRH agonist and antiandrogen
Study: NCT03838094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping
Study: NCT04061135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Response Inhibition and Deep Brain Stimulation in Parkinson's disease
Description: After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
Study: NCT04211220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A decision support software
Description: Insulin pump Continuous glucose monitoring
Study: NCT03526588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood
Description: 6×10\^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.
Study: NCT01871480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A:cytokine-induced killer cell +gefitinib
Description: CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B:Gefitinib
Description: Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
Study: NCT04042246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Provision
Description: Provide the information on the importance of the vaccination and tailored vaccination schedule
Study: NCT00511940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acamprosate
Description: 999 mg/day - 2997 mg/day, oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, placebo
Study: NCT02068898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XS003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XS003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XS003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasigna
Study: NCT01260675

Intervention type: DRUG
Intervention: Buprenorphine HCl/Naloxone HCl

Intervention type: DRUG
Intervention: Buprenorphine HCl/Naloxone HCl
Study: NCT00766753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic vaccine pulsed with multiple peptides
Description: Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The first booster vaccine phase:
Description: This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The second booster vaccine phase:
Description: At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays
Study: NCT02192424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Intermittent Insulin Therapy
Study: NCT01191567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VAC treatment
Description: wound treatment with VAC-therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: wound treatment with conventional treatment according to the hospitals local routines
Study: NCT00329901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY conjugate vaccine (MenACWY-CRM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY conjugate vaccine (MenACWY-CRM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: saline placebo
Description: 4.5 mg sodium chloride per 0.5 ml dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: saline placebo
Description: 4.5 mg sodium chloride per 0.5 ml dose
Study: NCT02289716

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 1 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg
Description: Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
Study: NCT02890108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar sweetened beverages
Description: 350 cc (1 can) of sugar sweetened beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificially sweetened beverages
Description: 350 cc (1 can) of artificially sweetened beverage
Study: NCT01585519

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High/ Low Epicatechin Apples/ Apple Extract/ Granules
Description: (Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High/ Low Epicatechin Apples/ Apple Extract/ Granules
Description: (Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High/ Low Epicatechin Apples/ Apple Extract/ Granules
Description: (Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High/ Low Epicatechin Apples/ Apple Extract/ Granules
Description: (Group 1) Low Apple Diet (i.e. \<1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily.
Study: NCT04579887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations
Description: Parkinsonian patients will undergo a two distinct experimental sessions, conducted in two separate days. In day 1, they will complete a series of validated and lab-tailored clinical evaluations, alongside with semi-structured interviews. These tests are designed to assess, the extent of the movement disorder, the predominance of positive symptoms and presence hallucination, potential cognitive impairment, amongst other relevant measures, for sleep assessment, loneliness, apathy and depression. In day 2 patients will perform the described robotic manipulation task in the MRI.
Study: NCT02083549

Intervention type: OTHER
Intervention: Blood collection
Description: After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
Study: NCT04656899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders messages to improve adherence.
Description: If the participant does not take their medicine at the correct time, a light on the smart pill cap begins to flash. If the bottle is not opened within 20 minutes, the Pillsy application sends an SMS text reminder to the participant's phone. If the bottle is not opened within 60 minutes, the participant receives an automated phone call. The participant may also receive brief motivational phrases or craving surveys that can be tailored to participant needs and preferences. Also, based on pre-populated and adjustable craving and withdrawal levels, the participants' provider could be contacted automatically based on the thresholds being crossed. Pillsy also includes a Pillsy Helpers feature in which the patient can name friends and family members who will also receive a text message notification one hour after a missed dose.
Study: NCT02407652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: 10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Cognitive Load Training
Description: 10 low cognitive load sessions, 400 trials each